ArticleGels (Basel, Switzerland)2025
Dosimetric Evaluation of the Sensitivity of PAGAT Gel Dosimeters Infused with Clinically Used Gadolinium-Based Contrast Agents.
Article in Gels (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dosimetric Characterization Using Quantitative Magnetic Resonance Imaging of PAGAT and Gd-PAGAT Polymer Gel Dosimeters at High Gd Concentration.Gels (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study evaluates the impact of gadolinium-based contrast agents (Omniscan, Dotarem, and Gadovist) on the performance of PAGAT gel dosimeters using spectrophotometric analysis. Dosimeters were infused with gadolinium at concentrations ranging from 0 to 40 mg/mL and irradiated with a 6 MV photon beam over a dose range of 0-15 Gy. Regarding dosimeter behavior, Dotarem exhibited an enhancement in optical density prior to irradiation due to polymerization reactions between the dosimeter and the contrast agent starting at 10 mg/mL, which compromised optical readings above 20 mg/mL. Omniscan consistently showed 37.7% lower sensitivity than standard PAGAT across all concentrations and dose levels. Conversely, Gadovist enhanced sensitivity by up to 50% at 20 mg/mL, with additional gains at higher concentrations, although accompanied by saturation at lower dose levels. Radiological analysis showed that all tested concentrations maintained mass energy-absorption coefficient differences below 1% and water-equivalence in effective atomic number within 5% at 6 MV. These findings underscore the importance of selecting an appropriate contrast agent to enhance gel dosimeter sensitivity, particularly in low-dose regions where measurement uncertainty increases. Additionally, gadolinium-infused PAGAT gels show strong potential for assessing dose enhancement phenomena. Their sensitivity, threshold behavior, and radiological properties suggest they may be suitable for applications in dose enhancement dosimetry as well as conventional clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.